First National Bank of Mount Dora Trust Investment Services reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 6.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,140 shares of the company’s stock after selling 4,503 shares during the period. Merck & Co., Inc. makes up 2.4% of First National Bank of Mount Dora Trust Investment Services’ portfolio, making the stock its 10th largest holding. First National Bank of Mount Dora Trust Investment Services’ holdings in Merck & Co., Inc. were worth $5,315,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Titan Capital Management LLC CA purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $25,000. LFA Lugano Financial Advisors SA boosted its stake in shares of Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after purchasing an additional 225 shares during the period. JJJ Advisors Inc. purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $27,000. Cumberland Partners Ltd purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $40,000. Finally, Fusion Family Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 268.2% during the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after purchasing an additional 354 shares during the period. Institutional investors own 74.97% of the company’s stock.

In other news, EVP Richard R. Deluca sold 6,427 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total value of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares in the company, valued at approximately $8,783,245.07. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is owned by insiders.

Merck & Co., Inc. stock traded up $0.52 during trading hours on Wednesday, hitting $83.81. The company had a trading volume of 534,363 shares, compared to its average volume of 10,285,667. The firm has a market cap of $216.07 billion, a P/E ratio of 19.31, a P/E/G ratio of 1.73 and a beta of 0.53. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. Merck & Co., Inc. has a 1 year low of $66.10 and a 1 year high of $87.35. The company has a 50-day moving average price of $84.66 and a two-hundred day moving average price of $82.22.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.14. The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.06 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 4.92 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 7th. Shareholders of record on Monday, September 16th were given a $0.55 dividend. The ex-dividend date was Friday, September 13th. This represents a $2.20 annualized dividend and a yield of 2.62%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.

A number of equities analysts recently commented on the stock. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Citigroup lifted their price target on shares of Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. They noted that the move was a valuation call. Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, June 21st. Finally, Bank of America set a $97.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $93.29.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.